Jabbar Kausar J, Medeiros L Jeffrey, Wang Sa A, Miranda Roberto N, Johnson Malisha R, Verstovsek Srdan, Jorgensen Jeffrey L
From the Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston.
Arch Pathol Lab Med. 2014 Sep;138(9):1210-4. doi: 10.5858/arpa.2013-0537-OA.
Mast cells of systemic mastocytosis (SM) have aberrant immunophenotypes that are useful for their detection by flow cytometry immunophenotyping.
To assess the usefulness of CD2, CD25, and other antigens for establishing the diagnosis of SM in bone marrow using flow cytometry immunophenotyping.
We studied 50 bone marrow aspirates of patients with SM using flow cytometry immunophenotyping. The bone marrow aspirates were stained with antibodies specific for CD2, CD25, CD35, CD59, CD63, and CD69. For the detection of CD2 and CD25, antibodies conjugated with phycoerythrin (PE) or fluorescein isothiocyanate (FITC) were compared. CD45-PerCP and CD117-APC were used for gating. Data were acquired on FACS Calibur cytometers and analyzed using CellQuest software.
CD2 and CD25 were positive in 41 of 50 (82%) and 45 of 50 (90%) SM cases, respectively. For CD2, the PE-conjugated antibody yielded better sensitivity than the FITC-conjugated antibody (31 of 40 [78%] versus 28 of 40 [70%]). For CD25, PE-conjugated and FITC-conjugated antibodies showed similar detection sensitivity, although the intensity of expression was brighter with CD25-PE. Compared with immunohistochemistry, flow cytometry immunophenotyping was superior for detecting CD2 (14 of 23 [61%] versus 9 of 23 [39%]). Other antigens frequently overexpressed in SM were CD35 (43 of 50 [86%]), CD59 (46 of 50 [92%]), CD63 (43 of 49 [88%]), and CD69 (39 of 48 [81%]).
Flow cytometry immunophenotyping is a rapid and sensitive technique for characterizing mast cells in bone marrow aspirate specimens. The use of PE-conjugated antibodies for CD2 and CD25 improves the detection rate (CD2) or facilitates analysis (CD25); therefore, PE-conjugated antibodies are suggested. Antibodies reactive with CD35, CD59, CD63, and CD69 are also helpful in detecting SM in bone marrow.
系统性肥大细胞增多症(SM)的肥大细胞具有异常免疫表型,这有助于通过流式细胞术免疫表型分析对其进行检测。
评估CD2、CD25和其他抗原在利用流式细胞术免疫表型分析诊断骨髓SM中的作用。
我们采用流式细胞术免疫表型分析研究了50例SM患者的骨髓穿刺液。骨髓穿刺液用针对CD2、CD25、CD35、CD59、CD63和CD69的特异性抗体进行染色。对于CD2和CD25的检测,比较了与藻红蛋白(PE)或异硫氰酸荧光素(FITC)偶联的抗体。使用CD45-藻红蛋白-叶绿素蛋白(PerCP)和CD117-别藻蓝蛋白(APC)进行设门。数据在FACS Calibur流式细胞仪上采集,并使用CellQuest软件进行分析。
在50例SM病例中,CD2和CD25阳性分别为41例(82%)和45例(90%)。对于CD2,PE偶联抗体的敏感性高于FITC偶联抗体(40例中的31例[78%]对40例中的28例[70%])。对于CD25,PE偶联和FITC偶联抗体显示出相似检测敏感性,尽管CD25-PE的表达强度更高。与免疫组织化学相比,流式细胞术免疫表型分析在检测CD2方面更具优势(23例中的14例[61%]对23例中的9例[39%])。在SM中经常过度表达的其他抗原为CD35(50例中的43例[86%])、CD59(50例中的46例[92%])、CD63(49例中的43例[88%])和CD69(48例中的39例[81%])。
流式细胞术免疫表型分析是一种用于鉴定骨髓穿刺液标本中肥大细胞的快速且敏感的技术。使用PE偶联抗体检测CD2可提高检测率,检测CD25则便于分析;因此,建议使用PE偶联抗体。与CD35、CD59、CD63和CD69反应的抗体也有助于检测骨髓中的SM。